Group 1 - The company expects a net profit attributable to shareholders of the parent company for the first half of 2025 to be between 300 million and 330 million yuan, an increase of 72.84 million to 102.84 million yuan compared to the same period last year, representing a year-on-year increase of 32.06% to 45.27% [3][5] - The expected net profit attributable to shareholders after deducting non-recurring gains and losses is also projected to be between 300 million and 330 million yuan, with a year-on-year increase of 30.78% to 43.86% [3][5] - The significant increase in profit is attributed to the company's competitive advantages in time and technology, as well as the expansion of its high-quality customer base, leading to substantial growth in sales revenue of peptide raw materials [6] Group 2 - The company completed the shareholding registration for the second vesting period of its 2023 restricted stock incentive plan, with a total of 1,232,616 shares to be listed on July 9, 2025 [12][14] - The total number of shares after the vesting will increase from 314,819,281 shares to 316,051,897 shares, without causing any change in the company's control [22][23] - The newly vested shares account for approximately 0.39% of the total shares before vesting, and are not expected to have a significant impact on the company's financial status and operating results [23]
江苏诺泰澳赛诺生物制药股份有限公司2025年半年度业绩预告的自愿性披露公告